Rhumbline Advisers Boosts Position in Neos Therapeutics, Inc. (NEOS)

Rhumbline Advisers boosted its holdings in Neos Therapeutics, Inc. (NASDAQ:NEOS) by 13.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 20,409 shares of the company’s stock after buying an additional 2,441 shares during the period. Rhumbline Advisers owned approximately 0.09% of Neos Therapeutics worth $149,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of NEOS. Teachers Advisors LLC raised its holdings in Neos Therapeutics by 16.3% in the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock valued at $149,000 after buying an additional 3,572 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Neos Therapeutics by 15.5% during the first quarter. Russell Investments Group Ltd. now owns 100,783 shares of the company’s stock valued at $725,000 after purchasing an additional 13,527 shares during the period. Wells Fargo & Company MN raised its stake in shares of Neos Therapeutics by 130.3% during the first quarter. Wells Fargo & Company MN now owns 48,030 shares of the company’s stock valued at $346,000 after purchasing an additional 27,174 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Neos Therapeutics by 37.1% during the first quarter. Bank of New York Mellon Corp now owns 59,841 shares of the company’s stock valued at $431,000 after purchasing an additional 16,191 shares during the period. Finally, UBS Group AG raised its stake in shares of Neos Therapeutics by 6.1% during the first quarter. UBS Group AG now owns 108,714 shares of the company’s stock valued at $783,000 after purchasing an additional 6,276 shares during the period. Hedge funds and other institutional investors own 44.29% of the company’s stock.

Shares of Neos Therapeutics, Inc. (NEOS) opened at 8.10 on Wednesday. Neos Therapeutics, Inc. has a 1-year low of $4.85 and a 1-year high of $9.60. The stock’s market cap is $227.45 million. The stock’s 50 day moving average is $8.88 and its 200-day moving average is $8.88.

Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.83). Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%. The firm had revenue of $4.91 million during the quarter. On average, analysts anticipate that Neos Therapeutics, Inc. will post ($3.11) EPS for the current year.

NEOS has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. ValuEngine upgraded shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 20th. BMO Capital Markets reiterated an “outperform” rating and set a $15.00 price objective on shares of Neos Therapeutics in a research note on Tuesday, June 20th. Cantor Fitzgerald initiated coverage on shares of Neos Therapeutics in a research note on Monday, July 31st. They set an “overweight” rating and a $20.00 price objective on the stock. Finally, Royal Bank Of Canada set a $12.00 price objective on shares of Neos Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $14.00.

TRADEMARK VIOLATION WARNING: “Rhumbline Advisers Boosts Position in Neos Therapeutics, Inc. (NEOS)” was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://transcriptdaily.com/2017/10/18/rhumbline-advisers-boosts-position-in-neos-therapeutics-inc-neos.html.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply